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Introduction
Acute promyelocytic leukemia (APL) is a special disease entity of acute myeloid leukemia (AML). With the clinical use of all-trans retinoic acid (ATRA), APL turns into the most curable form of AML. Majority of APL cases are characterized by the fusion between promyelocytic leukemia (PML) gene and retinoic acid receptor alpha (RARα) gene, which is the consequence of t(15;17)(q22;q21) chromosomal translocation. 2 Although PML-RARα fusion gene can be detected in more than 98%
of APL patients, 3 RARα is also found to be fused with other partner genes, [4] [5] [6] [7] [8] [9] [10] [11] such as promyelocytic leukemia zinc finger (PLZF), nucleophosmin (NPM), etc. The RARα portion within fusion proteins is conserved, containing B-F domains of RARα, which cover the DNA-binding and ligand-binding motifs, so that RARα can be combined with retinoid X receptor alpha (RXRα) to bind the retinoic acid responsive element (RARE). 1, 2 As a result, the fusion proteins usually form heterodimers with RXRα. 10, 12 A critical property that all RARα fusion proteins have in common is the ability to self-associate, forming homodimers 13 repeats in its C-terminal region. 15 Overexpression of TBLR1 was validated in lung cancer and breast cancer, and also found enriched in human hematopoietic stem cells. [16] [17] [18] Moreover, recurrent abnormality of TBLR1 gene locus was highlighted in ETV6-RUNX1 positive acute lymphoblastic leukemia (ALL) and high-risk childhood ALL and a novel rearrangement associated with TBLR1, TBLR1/TP63, was described in B-cell non-Hodgkin lymphoma recently. [19] [20] [21] Here, we reported a novel RARα fusion gene, TBLR1-RARα, which is generated by a t(3;17)(q26;q21) chromosomal rearrangement in a rare variant APL patient. In this
For personal use only. on . by guest www.bloodjournal.org From study, we identified the molecular characterization of TBLR1-RARα, illustrated the feature of the chimeric protein generated by TBLR1-RARα, clarified its pathogenesis in APL, and investigated its sensitivity to ATRA treatment. As far as we know, this is the first study demonstrating the involvement of TBLR1 gene in APL.
Materials and methods

Case report
T he patient 1, a 63-year-old man, was admitted due to fatigue, fever and skin Figure 1G ). The patient was treated in local hospital and died one month after relapse.
We also investigated another two APL patients harboring t(3;17) chromosomal translocation, their karyotypes were reported as following: 45-46,XY,t(3;17)(q27;q22), del(1) (q21),-7,del(7)(p13),del(7)(q22q34)[cp16]/46,XY [3] (patient 2) and 46,XX, t(3;17)(q21;q25),t(15;17)(q22;q12) [3] /46,XX [5] (patient 3). In patient 3, PML-RARα transcript was also detected by RT-PCR.
All patients gave informed consent and studies using patient samples were approved by the ethical advisory board of Institute of Hematology and Blood Diseases Hospital.
This study was conducted in accordance with the Declaration of Helsinki.
Cell lines and reagents
293T, CV-1 and HEK293 cells were maintained in Dulbecco's modified Eagle medium, K562, U937, HL-60 and NB4 cells in RPMI-1640 medium, and supplemented with 10% fetal bovine serum (HyClone). ATRA, polybrene were purchased from Sigma-Aldrich.
5'-rapid amplification of cDNA ends (5'-RACE)
5'-RACE was performed to amplify the unknown chimeric fusion transcript. BM samples were obtained from the above mentioned APL patient 1, and total RNA was extracted from BM mononuclear cells (BMMNCs) with RNAiso Plus (TaKaRa).
5'-RACE was performed with a SMARTer ® RACE cDNA Amplification kit (Clontech) according to manufacturer's instructions. Total RNA was used to synthesize the first-strand cDNA, and the universal primer A mix (UPM) and gene-specific primer (5'-GCGAGGGAGGGCTGGGCACTATCT-3') was used to amplify the unknown fusion partner of RARα. PCR products were purified, sequenced and compared with GenBank sequences.
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RNA isolation and RT-PCR
TBLR1-
Plasmid constructs
Full-length cDNA of TBLR1-RARα was cloned into both pcDNA3. 
Luciferase assay
The transcriptional activity of TBLR1-RARα was assessed by luciferase assay. 
Statistical analysis
Data were shown as mean ± standard deviation. The significance of differences between two groups was determined by Student's t-test. Data analyses were performed using SPSS 19.0 software package. Statistical significance threshold was set at 0.05, asterisks indicate significant differences (*p < 0.05, **p < 0.01, and ***p < 0.001 ). 
Results
Molecular cloning and identification of TBLR1-
TBLR1-RARα fusion proteins self-associate into homodimers and associate with RXRα into heterodimers
Up till now, all RARα fusion proteins reported share at least one feature in common that is the ability to self-associate, and to form homodimers. 2, 13 TBLR1 was reported to form homodimers through its LisH domain. 24 In order to examine whether TBLR1-RARα can form homodimers, Co-IP assays were performed. Like other RARα fusion proteins, Flag-tagged-TBLR1-RARα could co-immunoprecipitated with
Myc-tagged-TBLR1-RARα ( Figure 3A) , which indicated that TBLR1-RARα could self-associate and form homodimers. Whether ATRA has an effect on homodimer
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Heterodimerization with RXRα is important for RARα fusion proteins to bind RARE. 7, 10, 12 To investigate whether TBLR1-RARα could associate with RXRα, Co-IP assay was performed, and the result showed that Flag-tagged-TBLR1-RARα could co-immunoprecipitate with and colocalized with RXRα ( Figure 3C left panel, 3D ). In addition, treatment of 1μM ATRA for 48h couldn't completely disassociate the TBLR1-RARα/RXRα complexes ( Figure 3C , right panel and 3D).
TBLR1-RARα exhibits a distinct subcellular localization
The characteristics of subcellular distribution of RARα fusion proteins are different from each other and may contribute to the pathogenesis of APLs. 2, 14, 25 In our study, TBLR1-RARα was predominantly found in nucleus and a small amount of it in cytoplasm by immunoblotting ( Figure 4A ). Immunofluorescence analysis showed PML-RARα primarily localized in a microspeckled nuclear pattern, while RARα exhibited a diffuse nuclear pattern ( Figure 4B ), which was consistent with previous reports. 2, 14, 25 However, TBLR1-RARα demonstrated a distinct subcellular localization pattern and was diffusely distributed both in nucleus and cytoplasm.
Previous studies have indicated that ATRA treatment is associated with degradation and localization of RARα fusion proteins. 2, 14, 25 To investigate the effect of ATRA on expression and distribution of TBLR1-RARα, immunoblotting and immunofluorescence analysis were performed. The total amount of TBLR1-RARα was obviously decreased in cells after 1μM ATRA treatment for 48h ( Figure 4C ), so as the down-regulation of TBLR1-RARα in nucleus and cytoplasm ( Figure 4A ). But the subcellular distribution pattern of TBLR1-RARα was unchanged, it was still diffusely distributed both in nucleus and cytoplasm ( Figure 4D ). 
TBLR1-RARα functions as a transcriptional activator
and overlapped with SMRT, HDAC3 and TBL1 both in nucleus and cytoplasm in 293T cells, but not with RARα ( Figure 6C ).
In the presence of pharmacological doses of ATRA, some RARα fusion proteins, such as PML-RARα and NPM-RARα, release the transcriptional corepressors and recruit transcriptional activators to activate transcription. 2, 14, 26 Moreover, TBLR1 can mediate an exchange of N-CoR/SMRT corepressors for coactivator complexes upon ligand binding. 28, 32, 33 To gain insight into these effect of ATRA on TBLR1-RARα fusion protein, Co-IP and immunofluorescence analysis were performed. As shown in figure   6D (left panel) and 6E, TBLR1-RARα still interacted with N-CoR, SMRT and HDAC3 when exposed to 1μM ATRA for 48h, but no longer associated with mSIN3A.
However, in comparator Co-IPs, RARα could only interact with HDAC3, its interaction with N-CoR, SMRT and mSIN3A couldn't be detected any more when exposed to 1μM ATRA for 48h ( Figure 6D , right panel). In addition, the distribution of colocalization between TBLR1-RARα and corepressors were also altered. 
Discussion
In this study, we presented three case of APL with complex chromosomal rearrangement, t(3;17)(q26;q21),t(7;17)(q11.2;q21). Several groups have reported rare cases of APL involving t(3;17) chromosomal translocation, 35, 36 which is similar to what we found in our study. This suggests that t(3;17)(q26;q21) chromosomal translocation is recurrent. Case 1 failed to achieve CR with ATRA and MTZ. antibodies were used as primary antibodies, while DAPI was used for nuclear staining.
At least 100 cells were counted for colocalization analysis. Scale bar = 8μm. 
